跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 29 条关于
“delpacibart-etedesiran”
全部
29
临床试验
2
药物
6
机构
0
资讯
21
去年
FDA Lifts Partial Clinical Hold on Avidity Biosciences' Myotonic Dystrophy Drug, Delpacibart Etedesiran
2年前
Avidity's Delpacibart Etedesiran Granted FDA Breakthrough Therapy Designation for Myotonic Dystrophy Type 1
去年
FDA Lifts Clinical Hold on Avidity's Delpacibart Etedesiran (AOC 1001) for Myotonic Dystrophy Type 1
去年
FDA Lifts Partial Hold on Avidity Biosciences' Myotonic Dystrophy Drug, Stock Surges
去年
Avidity Biosciences Plans BLA Submission for Delpacibart Zotadirsen in DMD44 by Late 2025
去年
Japan Grants First Orphan Drug Designation for Myotonic Dystrophy Type 1 to Avidity's Del-desiran
3个月前
Novartis' Del-Brax Hits Primary Biomarker Endpoint in Phase I/II FSHD Trial, Paving Way for First Disease-Modifying Therapy
7个月前
Avidity's Del-desiran Shows Promise for Myotonic Dystrophy Type 1 in Phase 1/2 MARINA Trial Published in NEJM
去年
Advanced Drug Delivery Technologies Drive Biotech Innovation as Nanomedicine Market Approaches $430 Billion
9天前
Novartis' Del-desiran Misses Primary Endpoint in Phase 3 HARBOR, Rattling DMPK-Targeting Field
第 1 页,共 3 页
上一页
下一页